/

Società

En

Non verificato

Ensoma

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteScienza

9 comunicati stampa

Guarda tutti i comunicati

01/12/2025

Scienza

Biotecnologia

Medicina - Varie

Biologia

Salute

Farmaceutica

Industria

Ensoma Announces First Patient Dosed in Phase 1/2 Clinical Trial of EN-374 for Treatment of X-CGD

Fonte

Emittente

1.00

0

04/11/2025

Scienza

Biotecnologia

Biologia

Salute

Farmaceutica

Sanità

Oncologia

Eventi

Industria

Ensoma Presents Preclinical Data Demonstrating Potential of In Vivo, HSC-derived CAR-M, NK, and T Platform for Solid Tumors at SITC 2025

Fonte

Emittente

1.00

0

03/10/2025

Scienza

Biotecnologia

Salute

Farmaceutica

Sanità

Oncologia

Ensoma to Present New Preclinical Data at the Society for Immunotherapy of Cancer Annual Meeting

Fonte

Emittente

1.00

0

22/09/2025

Industria

Scienza

Biologia

Biotecnologia

Sanità

Salute

Medicina - Varie

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

Fonte

Emittente

1.00

0

12/05/2025

Industria

Salute

Igiene alimentare

Biologia

Biotecnologia

Scienza

Farmaceutica

Ensoma Announces FDA Clearance of IND Application for First In Vivo HSC-Directed Gene Insertion Therapy

Fonte

Emittente

1.00

0

29/04/2025

Eventi

Industria

Scienza

Biotecnologia

Farmaceutica

Oncologia

Sanità

Salute

Ensoma to Present Preclinical Data and Manufacturing Advancements for In Vivo HSC Engineering Platform to Treat Cancer, Immune Disorders and Genetic Diseases at ASGCT 28th Annual Meeting

Fonte

Emittente

1.00

0

13/02/2025

Scienza

HIV, AIDS e malattie autoimmuni

Igiene alimentare

Biotecnologia

Salute

Farmaceutica

Industria

Ensoma Receives Rare Pediatric Disease and Orphan Drug Designations for EN-374 for Treatment of Chronic Granulomatous Disease

Fonte

Emittente

1.00

0

05/11/2024

Eventi

Biologia

Biotecnologia

Sanità

Salute

Farmaceutica

Oncologia

Scienza

Medicina - Varie

Ensoma Unveils Three Programs Leveraging In Vivo Hematopoietic Stem Cell Engineering Platform to Target Genetic, Immune and Oncological Diseases

Fonte

Emittente

1.00

0

28/10/2024

Mercato del lavoro

Industria

Biotecnologia

Igiene alimentare

Sanità

Salute

Farmaceutica

Oncologia

Scienza

Medicina - Varie

Ensoma Appoints Accomplished Deal Maker Jon Garen as Chief Corporate Development and Business Officer

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0